Get in touch

VacTimmune

Revolutionising the Approach to Treating Infectious Diseases

TheAMR Challenge

The World Health Organisation (WHO) has identified certain antimicrobial-resistant organisms as critical threats to global health. These pathogens are fast becoming untreatable with conventional antibiotics, making them a clear and present danger. At VacTimmune, we’ve taken up the challenge to combat these AMR organisms head-on. Our research and development efforts are specifically targeted at creating vaccines to counteract these critical threats.

In a world where bacterial infections outpace our ability to fight them, VacTimmune offers hope and innovation. Our mission is to revolutionise infectious disease prevention and combat antimicrobial resistance (AMR) through vaccines. VacTimmune’s accelerated reverse vaccine discovery pipeline uses advanced in silico and in vitro techniques to quickly identify potential vaccines, which are then rigorously tested in relevant in vivo models to ensure their protective effectiveness.

The VacTimmuneVision

Our vision is simple but profound: a world where bacterial infections are no longer a formidable threat to human health. We’re committed to developing vaccines that can protect us from the ever-evolving world of infectious diseases and the alarming rise of AMR organisms.

Vaccines in Development

We are actively working on several vaccines, currently  in pre-clinical development, targeting a range of antibiotic-resistant bacteria and related health concerns:

Pseudomonas aeruginosa

Klebsiella pneumoniae

Enterobacter cloacae complex

Staphylococcus aureus

Streptococcus

Escherichia coli

Neonatal sepsis

Sexual health

Our Approach to Accelerated Vaccine Discovery

Our pipeline uses a unique combination of advanced computational methods and in vitro screening to identify promising vaccine candidates swiftly.

To ensure the effectiveness of our vaccine candidates, we subject them to rigorous in vivo testing, simulating real-world infection scenarios.

We collaborate with leading experts in microbiology, immunology, and bioinformatics to stay at the forefront of scientific discovery.

Our Team

Prof. Miguel Valvano

Member of Board of Directors
Prof. Miguel Valvano established a world-class programme on lipopolysaccharide (LPS) biogenesis and the molecular and cellular pathogenesis of opportunistic bacteria. His research has advanced the mechanistic of the biologically conserved processes involved in LPS O-antigen assembly and protein glycosylation in bacteria. His research has resulted in major contributions to increase our understanding of the molecular basis of intrinsic antimicrobial resistance.

Dr Paulina Zarodkiewicz

CSO
Dr Paulina Zarodkiewicz obtained her B.A. (Mod.) in Microbiology from Trinity College Dublin, Ireland and M.Sc in Molecular biology and biotechnology from Queen’s University Belfast, UK. Her PhD was part of the Marie Sklodowska Curie Actions ITN called Bactivax. Her research focused on identification of novel vaccine candidates against gram negative bacteria,  which she carried out within the labolatories of Prof Valvano and Dr Ingram at Wellcome-Wolfson Institute For Experimental Medicine, Queen’s University Belfast, UK.

Dr Beckie Ingram

CEO
Dr Beckie Ingram is a T-cell immunologist, with a track record in vaccine antigen discovery and characterisation of the immune response to bacterial pathogens. She has worked extensively on organisms with the potential for bioterrorism and developed the vaccine pipeline the company utilises. She also has extensive expertise with preclinical infection models She is a member of the UK BactiVac network and a PI of the All-Island Vaccine Research and Training Network (AIVRT) recently funded by an HEA North-South award to develop vaccines to prevent AMR respiratory pathogens.

Join Us in the Fight

The battle against bacterial infections and antimicrobial resistance is a formidable one, but with your support and our innovative approach to vaccine development, we believe that we can turn the tide. Together, we can build a safer, healthier future for generations to come.

Contact us today to learn more aabout our research, our team, and our vision. Together, we can create a world where bacterial infections are no longer a looming threat.